• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 5th February 2018

Alan Maynard – Alas No More

Tony Culyer writes on the contribution to health economics of Alan Maynard, the pioneering health economist, who died on February 2nd 2018. If you wanted to know what people thought of Alan Maynard, the pioneering health economist, and why they…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Tony Culyer writes on the contribution to health economics of Alan Maynard, the pioneering health economist, who died on February 2nd 2018.

If you wanted to know what people thought of Alan Maynard, the pioneering health economist, and why they thought it, you could not do better than to pick up a little yellow paperback book called Maynard Matters – Critical Thinking on Health Policy which will tell you nearly all you need to know about him and why he mattered.

He will be chiefly remembered as an uncompromising rubber of other people’s noses (especially those belonging to doctors, politicians and health service managers) in the ineluctable truths of economics. His economics was not over-sophisticated and he never blinded innocent mind with maths or weighty abstractions. Simple mainstream economic points, well-made, empirically bolstered, forcefully (often ironically) expressed and insightfully applied to serious problems – these are the hallmarks of classic Maynard the window-breaker (not my phrase but Virginia Bottomley’s – consult the yellow paperback). He could coin a phrase. My favourite is “NHS redisorganisation”, a very handy neologism for all students of health care in the UK. These talents made him a brilliant teacher. I can’t imagine anyone sleeping through an Alan Maynard lecture.

But. (There’s a good one-word sentence for you.) Look at that yellow paperback. The first half of it tells you what others thought of him. The second tells you what he thought – about regional inequalities in the NHS, putting the economics in evidence informed medicine where Cochrane and Sackett had stopped short, resisting the narrowing perspective of “health economics” as it tended to become identified with “cost-effectiveness analysis”, addiction and policies for behaviour change, manpower (as was once said) planning and role substitution in the clinical professions, misdirected training in public health management skills, redirecting policy focus from inputs to outputs, the need for rational rationing, competition and choice in the NHS, avoiding misplaced market idolatry, NHS disorganisation and redisorganisation, fallacious international comparisons of healthcare systems, general practice fund-holding, and sensible regulation of pharmaceuticals.

Nearly all of his writing across this wide portfolio of topics appeared in accessible places – most notably the Health Service Journal – that were not exclusively where economists write for economists. This was his greatest gift: to be able to summarise large literatures in approachable language with eagle-eyed targeting and dollops of irony to discomfort the complacent. It wasn’t his only gift. He also made notable contributions to the material summarised. He founded the Centre for Health Economics at York and nurtured it into an internationally dominant position. He directed the first UK Masters programme in health economics at York, which can convincingly claim still to be the world leader. He taught countless students and won and undertook dozens (possibly hundreds) of research grants. He was an indefatigable lecturer throughout the UK and abroad. He was a generous helper and supporter of other university centres of health economics expertise (notably Aberdeen, from which he had an honorary doctorate). He was a committed Chair of York Hospital for twelve years and of the Vale of York NHS Commissioning Group for four until his health began to fail. He received an OBE for his service to the NHS.

In these days, when academic merit is increasingly being reckoned in terms of “impact”, he surely stands alone as an outstanding health economist who really did make a difference.

Read the full obituary here.

Alan Maynard gave the 2013 OHE Annual Lecture on Contracting for Quality in the NHS.

Related Insights

Air balloon HTA v4
  • Insight
  • March 2023

Around The World in HTAs: Spain – Are We There Yet?

Read more
Informal Carer Burden Series: OHE on behalf of Roche
  • Insight
  • March 2023

Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA

Read more
Eye-Disease Gene-Therapies blog
  • Insight
  • February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Read more
Fishing on the lake at sunset. Fishing background.
  • Insight
  • February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!